In a Phase 1b study evaluating magrolimab and azacitidine in previously untreated AML patients (82.8% with TP53 mutations, of whom 79.2% had adverse-risk cytogenetics) (NCT03248479), 32.2% of patients achieved a CR, including 31.9% with TP53 mutations [119]. The gene discussed is TP53; the disease is acute myeloid leukemia.